Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 08:04   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this

  Be the first to like this.
 


 

4484  2612  530  329 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 SPY 186.39+0.265 
 BAC 16.15+0.02 
 FB 58.94-0.78 
 EEM 42.01+0.38 
 GE 26.56+0.44 
 QQQ 86.20+0.02 
 IWM 112.92+0.56 
 XLF 21.86+0.04 
 CSCO 23.21+0.18 
 MU 23.91+1.43 
Partners & Brokers